LRRK2 and Parkinson disease: Beyond the aforementioned challenges in designing G2019S-LRRK2 selective kinase inhibitors, it is an essential requirement for a successful PD therapeutic to be brain-penetrant; few reported examples of these exist, for example (3) (44).